Psyence Biomedical Ltd. Warrant (PBMWW) 10-Year Financial Performance & Capital Metrics

PBMWW • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutPsyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Show more

Revenue $0
EBITDA -$46M -1316.9%
Net Income -$51M -1495.5%
EPS (Diluted) 0.00
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -865.36

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-270.09%

5Y Avg-270.09%

3Y Avg-270.09%

Latest-

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Mar 2022	Mar 2023	Mar 2024
Sales/Revenue+	0	0	0
Revenue Growth %	-	-	-
Cost of Goods Sold+	0	0	0
COGS % of Revenue	-	-	-
Gross Profit+	0	0	0
Gross Margin %	-	-	-
Gross Profit Growth %	-	-	-
Operating Expenses+	1.86M	3.23M	46.69M
OpEx % of Revenue	-	-	-
Selling, General & Admin	1.72M	1.63M	1.8M
SG&A % of Revenue	-	-	-
Research & Development	137.24K	1.61M	954.59K
R&D % of Revenue	-	-	-
Other Operating Expenses	0	0	43.94M
Operating Income+	-1.85M	-3.23M	-45.81M
Operating Margin %	-	-	-
Operating Income Growth %	-	-0.74%	-13.17%
EBITDA+	-1.85M	-3.23M	-45.81M
EBITDA Margin %	-	-	-
EBITDA Growth %	-	-0.74%	-13.17%
D&A (Non-Cash Add-back)	0	0	240
EBIT	0	0	-50.17M
Net Interest Income+	0	1.55K	-50.81K
Interest Income	0	1.55K	2.13K
Interest Expense	0	0	52.94K
Other Income/Expense	-4.58K	26.91K	-5.35M
Pretax Income+	-1.86M	-3.21M	-51.16M
Pretax Margin %	-	-	-
Income Tax+	0	0	0
Effective Tax Rate %	1%	1%	1%
Net Income+	-1.86M	-3.21M	-51.16M
Net Margin %	-	-	-
Net Income Growth %	-	-0.73%	-14.96%
Net Income (Continuing)	-1.86M	-3.21M	-51.16M
Discontinued Operations	0	0	0
Minority Interest	0	0	0
EPS (Diluted)+	0.00	0.00	0.00
EPS Growth %	-	-	-
EPS (Basic)	0.00	0.00	0.00
Diluted Shares Outstanding	0	0	0
Basic Shares Outstanding	0	0	0
Dividend Payout Ratio	-	-	-

Balance Sheet

	Mar 2022	Mar 2023	Mar 2024
Total Current Assets+	1.83M	1.59M	1.13M
Cash & Short-Term Investments	1.75M	1.33M	733.19K
Cash Only	1.75M	1.33M	733.19K
Short-Term Investments	0	0	0
Accounts Receivable	39.55K	149.37K	41.75K
Days Sales Outstanding	-	-	-
Inventory	0	0	0
Days Inventory Outstanding	-	-	-
Other Current Assets	36.23K	29.56K	29.61K
Total Non-Current Assets+	0	0	5.49K
Property, Plant & Equipment	0	0	5.49K
Fixed Asset Turnover	-	-	-
Goodwill	0	0	0
Intangible Assets	0	0	0
Long-Term Investments	0	0	0
Other Non-Current Assets	0	0	0
Total Assets+	1.83M	1.59M	1.13M
Asset Turnover	-	-	-
Asset Growth %	-	-0.13%	-0.29%
Total Current Liabilities+	131.76K	1.79M	12.1M
Accounts Payable	36.89K	1.63M	562.35K
Days Payables Outstanding	-	-	-
Short-Term Debt	0	0	10.45M
Deferred Revenue (Current)	0	0	0
Other Current Liabilities	0	0	968.51K
Current Ratio	13.90x	0.89x	0.09x
Quick Ratio	13.90x	0.89x	0.09x
Cash Conversion Cycle	-	-	-
Total Non-Current Liabilities+	0	0	0
Long-Term Debt	0	0	0
Capital Lease Obligations	0	0	0
Deferred Tax Liabilities	0	0	0
Other Non-Current Liabilities	0	0	0
Total Liabilities	131.76K	1.79M	12.1M
Total Debt+	0	0	10.45M
Net Debt	-1.75M	-1.33M	9.71M
Debt / Equity	-	-	-
Debt / EBITDA	-	-	-
Net Debt / EBITDA	-	-	-
Interest Coverage	-	-	-865.36x
Total Equity+	1.7M	-200.44K	-10.97M
Equity Growth %	-	-1.12%	-53.74%
Book Value per Share	-	-	-
Total Shareholders' Equity	1.7M	-200.44K	-10.97M
Common Stock	0	0	46.13M
Retained Earnings	0	0	-57.46M
Treasury Stock	0	0	0
Accumulated OCI	0	0	361.06K
Minority Interest	0	0	0

Cash Flow

	Mar 2022	Mar 2023	Mar 2024
Cash from Operations+	-1.4M	-1.59M	-2.95M
Operating CF Margin %	-	-	-
Operating CF Growth %	-	-0.14%	-0.85%
Net Income	-1.86M	-3.21M	-51.16M
Depreciation & Amortization	0	0	240
Stock-Based Compensation	332.07K	221.29K	317.88K
Deferred Taxes	0	0	0
Other Non-Cash Items	0	-84.5K	49.07M
Working Capital Changes	129.74K	1.48M	-1.17M
Change in Receivables	100.05K	0	107.62K
Change in Inventory	0	0	0
Change in Payables	0	0	0
Cash from Investing+	-32.04K	0	-5.73K
Capital Expenditures	0	0	-5.73K
CapEx % of Revenue	-	-	-
Acquisitions	-	-	-
Investments	-	-	-
Other Investing	-32.04K	0	0
Cash from Financing+	-1.63M	1.17M	2.35M
Debt Issued (Net)	-	-	-
Equity Issued (Net)	-	-	-
Dividends Paid	0	0	0
Share Repurchases	-	-	-
Other Financing	-1.63M	1.17M	0
Net Change in Cash	-	-	-
Free Cash Flow+	-1.4M	-1.59M	-2.95M
FCF Margin %	-	-	-
FCF Growth %	-	-0.14%	-0.85%
FCF per Share	-	-	-
FCF Conversion (FCF/Net Income)	0.75x	0.50x	0.06x
Interest Paid	0	0	0
Taxes Paid	0	0	0

Key Ratios

Metric	2021	2022	2023
Return on Equity (ROE)	-109.29%	-427.58%	-
Interest Coverage	-	-	-865.36x
FCF Conversion	0.75x	0.50x	0.06x

Frequently Asked Questions

Growth & Financials

Psyence Biomedical Ltd. Warrant (PBMWW) grew revenue by 0.0% over the past year. Growth has been modest.

Psyence Biomedical Ltd. Warrant (PBMWW) reported a net loss of $51.2M for fiscal year 2023.

Dividend & Returns

Psyence Biomedical Ltd. Warrant (PBMWW) had negative free cash flow of $3.0M in fiscal year 2023, likely due to heavy capital investments.

← Back to Screener